Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
Provider: Zacks Investment Research Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Verastem Inc Receives Orphan Drug Designation from U.S. FDA For Defactinib In Mesothelioma

Wednesday, 24 Jul 2013 07:00am EDT 

Verastem, Inc. announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of mesothelioma, a rare form of lung cancer. The designation is designed to encourage the development of drugs which may provide benefit to patients suffering from rare diseases. 

Company Quote

0.29 +3.10%
18 Sep 2014